<b>AI TRADING BOT - POST-MARKET REPORT</b>
<b>Monday, September 29, 2025</b>
<b>12:35 PM ET</b>
=============================================

<b>DUAL-STRATEGY PORTFOLIO OVERVIEW</b>
Total Portfolio Value: <b>$281,324.30</b>
Total Unrealized P&L: <b>$+10,214.07</b>
Total Return: <b>+5.11%</b>
Active Positions: <b>33</b>
Strategy Split: <b>DEE 49% | SHORGAN 51%</b>

<b>==== DEE-BOT (Beta-Neutral S&P 100) ====</b>
Strategy: <b>Beta-Neutral S&P 100</b>
Portfolio Value: <b>$109,863.31</b>
Position Value: <b>$109,863.31</b>
Cash Available: <b>$0.00</b>
Unrealized P&L: <b>$+3,821.57</b>
Positions: <b>12 large-caps</b>
Portfolio Beta: <b>~1.0 (target)</b>
Best: <b>AAPL (+11.85%)</b>
Worst: <b>HD (-2.79%)</b>

<b>==== SHORGAN-BOT (Catalyst Trading) ====</b>
Strategy: <b>Catalyst Trading</b>
Portfolio Value: <b>$171,460.99</b>
Position Value: <b>$171,460.99</b>
Cash Available: <b>$0.00</b>
Unrealized P&L: <b>$+6,392.50</b>
Positions: <b>21 catalyst plays</b>
Focus: <b>FDA events, earnings, momentum</b>
Best: <b>RGTI (+93.97%)</b>
Worst: <b>EMBC (-9.00%)</b>

<b>UPCOMING CATALYSTS</b>
<b>Tomorrow (Sept 17):</b> CBRL Earnings
   - 81 shares positioned for potential squeeze
<b>Thursday (Sept 19):</b> INCY FDA Decision
   - 61 shares positioned for binary approval

<b>RISK ASSESSMENT</b>
Capital Deployed: <b>$281,324.30</b>
Capital Exposure: <b>140.7%</b>
<b>HIGH EXPOSURE WARNING</b>

<b>SYSTEM STATUS</b>
Multi-Agent Analysis: <b>ACTIVE</b>
Risk Management: <b>ACTIVE</b>
Stop Losses: <b>PROTECTED</b>
Portfolio Monitoring: <b>24/7</b>

=============================================
<b>Next Report:</b> Tomorrow 4:15 PM ET
<b>Status:</b> FULLY OPERATIONAL